Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.57 |
| ▸ | BMP1 | P13497 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | RAD52 | P43351 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | GRK2 | P25098 | 2/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709537 | 0.95 | GHSR (0.63) | GHSRBMP1KMT2ARAD52TAS2R14 | |
| SCHEMBL1709659 | 0.74 | GHSR (0.41) | GHSRKMT2AMEN1POLB | |
| SCHEMBL1990385 | 0.73 | GHSR (1.00) | GHSRBMP1KMT2ARAD52TAS2R14 | |
| SCHEMBL10121785 | 0.71 | BMP1 (0.37) | GHSRBMP1KMT2AUSP2MEN1 | |
| SCHEMBL10122296 | 0.70 | GHSR (0.72) | GHSRKMT2ARAD52USP2ESR1 | |
| SCHEMBL10122297 | 0.70 | GHSR (0.72) | GHSRKMT2ARAD52USP2CXCR3 | |
| SCHEMBL1990209 | 0.70 | GHSR (0.75) | GHSRKMT2ARAD52MCHR1USP2 | |
| SCHEMBL1988332 | 0.70 | GHSR (0.75) | GHSRKMT2ARAD52MCHR1USP2 | |
| SCHEMBL1989162 | 0.70 | GHSR (0.86) | GHSRKMT2ARAD52TAS2R14USP2 | |
| SCHEMBL1989937 | 0.70 | GHSR (0.86) | GHSRKMT2ARAD52TAS2R14USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | GHSR, GHRHR, STS | GHSR 1/4885BMP1 2622/4885KMT2A 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.